Skip to main content

Session Coverage

January 24, 2020
George Adams, MD, MHS, MBA, presented six-month data from the Tack Optimized Balloon Angioplasty II (TOBA II) Below the Knee (BTK) trial Friday morning at the International Symposium on Endovascular Therapy (ISET).
January 24, 2020
In an afternoon session at the International Symposium on Endovascular Therapy, presenters reviewed practical tips and techniques for treating patients with complex critical limb ischemia (CLI) and peripheral arterial disease (PAD).
January 24, 2020
Hollywood, FL (January 24, 2020) – The Supera stent (Abbott Vascular) is a “fundamentally different design”, said Bret Wiechmann, MD, of Vascular & Interventional Physicians in Gainesville, Florida, in his Friday morning presentation on the…
January 24, 2020
Michael R. Jaff, DO, Vice President of Clinical Affairs, Innovation, Technology and Peripheral Interventions at Boston Scientific, presented results from the COMPARE Pilot randomized clinical trial on Friday morning at the International Symposium on…
January 23, 2020
The study design of a recently published meta-analysis by Katasanos and colleagues is flawed, according to a critique presented by William Gray, MD, at the International Symposium on Endovascular Therapy (ISET).
January 23, 2020
Hollywood, FL (January 23, 2020)- Results of the IN.PACT DEEP Global study show durable effectiveness and safety of the IN.PACT Admiral drug-coated balloon (DCB) (Medtronic) through 4 years, according to data presented by Gunnar Tepe, MD, at the…
January 23, 2020
Hollywood, FL (January 23, 2020) – In the first and only head-to-head comparison of two paclitaxel-eluting stents used in peripheral intervention, no difference was seen for the primary endpoint of primary patency at 24 months. Clinical improvements…
January 23, 2020
The Stellarex drug-coated balloon (DCB) (Philips) showed “excellent” safety and effectiveness in a real-world population of patients with complex peripheral artery disease (PAD).
January 23, 2020
Findings from 7 different real-world data sources show no difference in survival following treatment with drug-coated and non-drug-coated devices, according to a presentation given today at the International Symposium on Endovascular Therapy (ISET).
January 23, 2020
Hollywood, FL (January 23, 2020) – In a pooled analysis that included more than 1000 patients treated with the Lutonix 035 drug-coated balloon (DCB) (BD), no increase in mortality risk was seen compared to those treated with uncoated balloon…
Back to Top